Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

NCT02549209 is registered in ClinicalTrials.gov with Daniela Matei, MD as lead sponsor.

NCT NCT02549209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
Lead sponsor
Daniela Matei, MD
Phase
Phase 2
Overall status
Completed
Start date
August 22, 2017
Completion date
February 10, 2022
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer